China Pharma Holding (China Pharma Holding) Long-Term Capital Lease Obligation : $0.04 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Long-Term Capital Lease Obligation?

China Pharma Holding's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil.

China Pharma Holding's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.08 Mil) to Sep. 2023 ($0.06 Mil) and declined from Sep. 2023 ($0.06 Mil) to Dec. 2023 ($0.04 Mil).

China Pharma Holding's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.04 Mil).

China Pharma Holding Long-Term Capital Lease Obligation Historical Data

The historical data trend for China Pharma Holding's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding Long-Term Capital Lease Obligation Chart

China Pharma Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.05

0.04

China Pharma Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.08	0.06	0.04

China Pharma Holding (OTCPK:CPHI) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

China Pharma Holding Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding (China Pharma Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216

Website

https://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Executives

Ke Deng	10 percent owner	NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung	officer: Chief Financial Officer	72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett	director	4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang	director	NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong	director	NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui	director, 10 percent owner	FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li	officer: President and CEO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang	officer: Secretary	NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu	officer: CFO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond	10 percent owner	174 FM 1830, ARGYLE TX 76226
David F Brigante	10 percent owner	174FM 1830, ARGYLE TX 76226
Marat Rosenberg	10 percent owner	17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp	10 percent owner	174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc	10 percent owner	174 FM 1830, ARGYLE TX 76226
Timothy P Halter	director, 10 percent owner, officer: CEO, President & CFO	174 FM 1830, ARGYLE TX 76226